Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All sotrovimab studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchSotrovimabSotrovimab (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Real-world clinical outcomes of treatment with molnupiravir for patients with mild- to-moderate coronavirus disease 2019 during the Omicron variant pandemic

Suzuki et al., Research Square, doi:10.21203/rs.3.rs-2118653/v1
Oct 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
0 0.5 1 1.5 2+ Progression -8% Improvement Relative Risk Sotrovimab  Suzuki et al.  EARLY TREATMENT Is early treatment with sotrovimab beneficial for COVID-19? Retrospective 1,929 patients in Japan No significant difference in progression c19early.org Suzuki et al., Research Square, October 2022 Favors sotrovimab Favors control
Sotrovimab for COVID-19
40th treatment shown to reduce risk in May 2023
 
*, now known with p = 0.0017 from 22 studies, recognized in 38 countries. Efficacy is variant dependent.
Lower risk for hospitalization.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,200+ studies for 70+ treatments. c19early.org
Retrospective 1,921 patients in Japan, showing no significant difference in progression with sotrovimab use.
Efficacy is variant dependent. In Vitro studies predict lower efficacy for BA.11-3, BA.4, BA.54, XBB.1.9.3, XBB.1.5.24, XBB.2.9, CH.1.15, and no efficacy for BA.26, ХВВ.1.9.1, XBB.1.16, BQ.1.1.45, and CL.15. US EUA has been revoked.
risk of progression, 8.3% higher, OR 1.08, p = 0.73, treatment 672, control 1,257, adjusted per study, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Suzuki et al., 5 Oct 2022, retrospective, Japan, preprint, 53 authors. Contact: shibatay@fmu.ac.jp.
This PaperSotrovimabAll
Real-world clinical outcomes of treatment with molnupiravir for patients with mild- to-moderate coronavirus disease 2019 during the Omicron variant pandemic
Yasuhito Suzuki, Yoko Shibata, Hiroyuki Minemura, Takefumi Nikaido, Yoshinori Tanino, Atsuro Fukuhara, Ryuzo Kanno, Hiroyuki Saito, Shuzo Suzuki, Yayoi Inokoshi, Eiichiro Sando, Hirofumi Sakuma, Tatsuho Kobayashi, Hiroaki Kume, Masahiro Kamimoto, Hideko Aoki, Akira Takama, Taku Iizuka, Takamichi Kamiyama, Masaru Nakayama, Kiyoshi Saito, Koichi Tanigawa, Masahiko Sato, Yuichi Waragai, Toshiyuki Kambe, Norio Kanzaki, Teruhisa Azuma, Hiromasa Okamoto, Keiji Sakamoto, Yuichi Nakamura, Hiroshi Ohtani, Mitsuru Waragai, Shinsaku Maeda, Tokiya Ishida, Keishi Sugino, Wataru Abe, Yasuhiko Tsukada, Tomoyoshi Lee, Ryuki Yamada, Riko Sato, Takumi Onuma, Hikaru Tomita, Mikako Saito, Natsumi Watanabe, Mami Rikimaru, Takaya Kawamata, Julia Morimoto, Ryuichi Togawa, Yuki Sato, Junpei Saito, Kenya Kanazawa, Sugihiro Hamaguchi, Ken Iseki
doi:10.21203/rs.3.rs-2118653/v1
Background It is unclear whether molnupiravir has a bene cial effect on vaccinated patients infected with the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We here evaluated the e cacy of molnupiravir in patients with mild-to-moderate coronavirus disease 2019 (COVID-19) during the Omicron variant surge in Fukushima Prefecture, Japan. Methods We enrolled patients with mild-to-moderate COVID-19 who were admitted to hospitals between January and April, 2022. Clinical deterioration after admission was compared between molnupiravir users (n = 281) and non-users (n = 1,636). Results The molnupiravir users were older (P < 0.0001), and had greater rates of history of chronic respiratory disease (P = 0.039), hypertension (P < 0.0001), dyslipidemia (P < 0.0001), diabetes mellitus (P < 0.0001), and cardiac disease (P = 0.003) than the non-users. The clinical deterioration rate was signi cantly lower in the molnupiravir users compared to the non-users (3.92% vs 7.46%; P = 0.021). Multivariate logistic regression analysis demonstrated that receiving molnupiravir was a factor for preventing deterioration (odds ratio 0.426; 95% con dence interval 0.208-0.871; P = 0.019), independent of receiving the SARS-CoV-2 vaccine. Furthermore, in 259 patients who were selected from each group after matching on the propensity score, the rate of deterioration was signi cantly lower among those receiving molnupiravir compared to those not receiving molnupiravir (3.86% vs 9.65%; p = 0.008). Conclusion This real-world study demonstrates that molnupiravir contributes to the prevention of deterioration in COVID-19 patients after hospitalization during the Omicron variant phase.
Author contribution Conception and design: Yasuhito Suzuki and Yoko Shibata. Analysis and drafting the manuscript: Yasuhito Suzuki and Yoko Shibata. Data curation: all authors. Final approval of the manuscript: all authors. Ethic This study was performed in line with the principles of the Declaration of Helsinki. The protocol was approved by the local ethical committee. Consent to publication The authors seen the nal version of the manuscript and approved submission for publication.
References
Aggarwal, Beaty, Bennett, Real World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients, J Infect Dis, doi:10.1093/infdis/jiac206
Austin, Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies, Pharm Stat, doi:10.1002/pst.433
Bernal, Da Silva, Musungaie, Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients, N Engl J Med, doi:10.1056/NEJMoa2116044
Bojkova, Widera, Ciesek, Wass, Michaelis et al., Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates, Cell Res, doi:10.1038/s41422-022-00619-9
Callaway, Heavily mutated Omicron variant puts scientists on alert, Nature, doi:10.1038/d41586-021-03552-w
Carlos, Wong, Lau, Lau, Cowling et al., Realworld effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study, Lancet Infect Dis, doi:10.1016/S1473-3099(22)00507-2
Gupta, Gonzalez-Rojas, Juarez, Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial, Jama, doi:10.1001/jama.2022.2832
Hammond, Leister-Tebbe, Gardner, Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2118542
Hirotsu, Maejima, Shibusawa, SARS-CoV-2 Omicron sublineage BA.2 replaces BA.1.1: Genomic surveillance in Japan from September 2021 to March 2022, J Infect, doi:10.1016/j.jinf.2022.04.040
Hoffmann, Krüger, Schulz, The Omicron variant is highly resistant against antibodymediated neutralization: Implications for control of the COVID-19 pandemic, Cell, doi:10.1016/j.cell.2021.12.032
Korber, Fischer, Gnanakaran, Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus, Cell, doi:10.1016/j.cell.2020.06.043
Liu, Rocklöv, The effective reproductive number of the Omicron variant of SARS-CoV-2 is several times relative to Delta, J Travel Med, doi:10.1093/jtm/taac037
Ohashi, Hishiki, Akazawa, Different e cacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2 Antiviral Res, doi:10.1016/j.antiviral.2022.105372
Ong, Ren, Lee, Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study, Antibiotics, doi:10.3390/antibiotics11030345
Polack, Thomas, Kitchin, Safety and E cacy of the BNT162b2 mRNA Covid-19 Vaccine, N Engl J Med, doi:10.1056/NEJMoa2034577
Ren, Nishimura, Tjan, Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron's outbreak, PLoS One, doi:10.1371/journal.pone.0266270
Rosenke, Okumura, Lewis, MK-4482) is e cacious against Omicron and other SARS-CoV-2 variants in the Syrian hamster COVID-19 model, doi:10.1101/2022.02.22.481491v1
Shiba, Kawahara, Using Propensity Scores for Causal Inference: Pitfalls and Tips, J Epidemiol, doi:10.2188/jea.JE20210145
Shibata, Minemura, Suzuki, Development and external validation of the DOAT and DOATS scores: simple decision support tools to identify disease progression among nonelderly patients with mild/moderate COVID-19, doi:10.1101/2021.12.13.21267698v1
Takashita, Kinoshita, Yamayoshi, E cacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2, N Engl J Med, doi:10.1056/NEJMc2201933
Vanblargan, Errico, Halfmann, An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies, Nat Med, doi:10.1038/s41591-021-01678-y
Weinreich, Sivapalasingam, Norton, REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2035002
Yamamoto, Wada, Ichikawa, Evaluation of Biomarkers of Severity in Patients with COVID-19 Infection, J Clin Med, doi:10.3390/jcm10173775
{ 'institution': [{'name': 'Research Square'}], 'indexed': {'date-parts': [[2022, 10, 5]], 'date-time': '2022-10-05T19:12:35Z', 'timestamp': 1664997155368}, 'posted': {'date-parts': [[2022, 10, 5]]}, 'group-title': 'In Review', 'reference-count': 26, 'publisher': 'Research Square Platform LLC', 'license': [ { 'start': { 'date-parts': [[2022, 10, 5]], 'date-time': '2022-10-05T00:00:00Z', 'timestamp': 1664928000000}, 'content-version': 'unspecified', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2022, 9, 30]]}, 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:p>Background\n' ' It is unclear whether molnupiravir has a beneficial effect on vaccinated patients infected ' 'with the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We ' 'here evaluated the efficacy of molnupiravir in patients with mild-to-moderate coronavirus ' 'disease 2019 (COVID-19) during the Omicron variant surge in Fukushima Prefecture, Japan.\n' 'Methods\n' ' We enrolled patients with mild-to-moderate COVID-19 who were admitted to hospitals between ' 'January and April, 2022. Clinical deterioration after admission was compared between ' 'molnupiravir users (n\u2009=\u2009281) and non-users (n\u2009=\u20091,636).\n' 'Results\n' ' The molnupiravir users were older (P\u2009&lt;\u20090.0001), and had greater rates of ' 'history of chronic respiratory disease (P\u2009=\u20090.039), hypertension (P\u2009&lt;\u2009' '0.0001), dyslipidemia (P\u2009&lt;\u20090.0001), diabetes mellitus (P\u2009&lt;\u20090.0001), ' 'and cardiac disease (P\u2009=\u20090.003) than the non-users. The clinical deterioration rate ' 'was significantly lower in the molnupiravir users compared to the non-users (3.92% vs 7.46%; ' 'P\u2009=\u20090.021). Multivariate logistic regression analysis demonstrated that receiving ' 'molnupiravir was a factor for preventing deterioration (odds ratio 0.426; 95% confidence ' 'interval 0.208–0.871; P\u2009=\u20090.019), independent of receiving the SARS-CoV-2 vaccine. ' 'Furthermore, in 259 patients who were selected from each group after matching on the ' 'propensity score, the rate of deterioration was significantly lower among those receiving ' 'molnupiravir compared to those not receiving molnupiravir (3.86% vs 9.65%; p\u2009=\u2009' '0.008).\n' 'Conclusion\n' ' This real-world study demonstrates that molnupiravir contributes to the prevention of ' 'deterioration in COVID-19 patients after hospitalization during the Omicron variant ' 'phase.</jats:p>', 'DOI': '10.21203/rs.3.rs-2118653/v1', 'type': 'posted-content', 'created': {'date-parts': [[2022, 10, 5]], 'date-time': '2022-10-05T18:37:20Z', 'timestamp': 1664995040000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Real-world clinical outcomes of treatment with molnupiravir for patients with mild- to-moderate ' 'coronavirus disease 2019 during the Omicron variant pandemic', 'prefix': '10.21203', 'author': [ { 'given': 'Yasuhito', 'family': 'Suzuki', 'sequence': 'first', 'affiliation': [{'name': 'Fukushima Medical University'}]}, { 'given': 'Yoko', 'family': 'Shibata', 'sequence': 'additional', 'affiliation': [{'name': 'Fukushima Medical University'}]}, { 'given': 'Hiroyuki', 'family': 'Minemura', 'sequence': 'additional', 'affiliation': [{'name': 'Fukushima Medical University'}]}, { 'given': 'Takefumi', 'family': 'Nikaido', 'sequence': 'additional', 'affiliation': [{'name': 'Fukushima Medical University'}]}, { 'given': 'Yoshinori', 'family': 'Tanino', 'sequence': 'additional', 'affiliation': [{'name': 'Fukushima Medical University'}]}, { 'given': 'Atsuro', 'family': 'Fukuhara', 'sequence': 'additional', 'affiliation': [{'name': 'Ohara General Hospital'}]}, { 'given': 'Ryuzo', 'family': 'Kanno', 'sequence': 'additional', 'affiliation': [{'name': 'Fukushima Red Cross Hospital'}]}, { 'given': 'Hiroyuki', 'family': 'Saito', 'sequence': 'additional', 'affiliation': [{'name': 'Fujita General Hospital'}]}, { 'given': 'Shuzo', 'family': 'Suzuki', 'sequence': 'additional', 'affiliation': [{'name': 'Fujita General Hospital'}]}, { 'given': 'Yayoi', 'family': 'Inokoshi', 'sequence': 'additional', 'affiliation': [{'name': 'Saiseikai Fukushima General Hospital'}]}, { 'given': 'Eiichiro', 'family': 'Sando', 'sequence': 'additional', 'affiliation': [{'name': 'Fukushima Medical University'}]}, { 'given': 'Hirofumi', 'family': 'Sakuma', 'sequence': 'additional', 'affiliation': [{'name': 'Saiseikai Kawamata Hospital'}]}, { 'given': 'Tatsuho', 'family': 'Kobayashi', 'sequence': 'additional', 'affiliation': [{'name': 'Aizu Chuo Hospital'}]}, { 'given': 'Hiroaki', 'family': 'Kume', 'sequence': 'additional', 'affiliation': [{'name': 'Fukushima Medical University'}]}, { 'given': 'Masahiro', 'family': 'Kamimoto', 'sequence': 'additional', 'affiliation': [{'name': 'Takeda General Hospital'}]}, { 'given': 'Hideko', 'family': 'Aoki', 'sequence': 'additional', 'affiliation': [{'name': 'Bange Kousei General Hospital'}]}, { 'given': 'Akira', 'family': 'Takama', 'sequence': 'additional', 'affiliation': [{'name': 'Yurin Hospital'}]}, { 'given': 'Taku', 'family': 'Iizuka', 'sequence': 'additional', 'affiliation': [{'name': 'Yurin Hospital'}]}, { 'given': 'Takamichi', 'family': 'Kamiyama', 'sequence': 'additional', 'affiliation': [{'name': 'Iwaki City Medical Center'}]}, { 'given': 'Masaru', 'family': 'Nakayama', 'sequence': 'additional', 'affiliation': [{'name': 'Kashima Hospital'}]}, { 'given': 'Kiyoshi', 'family': 'Saito', 'sequence': 'additional', 'affiliation': [{'name': 'Fukushima Rosai Hospital'}]}, { 'given': 'Koichi', 'family': 'Tanigawa', 'sequence': 'additional', 'affiliation': [{'name': 'Futaba Medical Center'}]}, { 'given': 'Masahiko', 'family': 'Sato', 'sequence': 'additional', 'affiliation': [{'name': 'Soma General Hospital'}]}, { 'given': 'Yuichi', 'family': 'Waragai', 'sequence': 'additional', 'affiliation': [{'name': 'Soma General Hospital'}]}, { 'given': 'Toshiyuki', 'family': 'Kambe', 'sequence': 'additional', 'affiliation': [{'name': 'Minamisoma Municipal General Hospital'}]}, { 'given': 'Norio', 'family': 'Kanzaki', 'sequence': 'additional', 'affiliation': [{'name': 'Onahama Chuo Clinic'}]}, { 'given': 'Teruhisa', 'family': 'Azuma', 'sequence': 'additional', 'affiliation': [ { 'name': 'Shirakawa Satellite for Teaching and Research, Fukushima Medical ' 'University'}]}, { 'given': 'Hiromasa', 'family': 'Okamoto', 'sequence': 'additional', 'affiliation': [{'name': 'Shirakawa Kosei Hospital'}]}, { 'given': 'Keiji', 'family': 'Sakamoto', 'sequence': 'additional', 'affiliation': [{'name': 'Hoshi General Hospital'}]}, { 'given': 'Yuichi', 'family': 'Nakamura', 'sequence': 'additional', 'affiliation': [{'name': 'Hoshi General Hospital'}]}, { 'given': 'Hiroshi', 'family': 'Ohtani', 'sequence': 'additional', 'affiliation': [{'name': 'Iwase General Hospital'}]}, { 'given': 'Mitsuru', 'family': 'Waragai', 'sequence': 'additional', 'affiliation': [{'name': 'Southern TOHOKU General Hospital'}]}, { 'given': 'Shinsaku', 'family': 'Maeda', 'sequence': 'additional', 'affiliation': [{'name': 'Jusendo General Hospital'}]}, { 'given': 'Tokiya', 'family': 'Ishida', 'sequence': 'additional', 'affiliation': [{'name': 'Ohta Nishinouchi Hospital'}]}, { 'given': 'Keishi', 'family': 'Sugino', 'sequence': 'additional', 'affiliation': [{'name': 'Tsuboi Hospital'}]}, { 'given': 'Wataru', 'family': 'Abe', 'sequence': 'additional', 'affiliation': [{'name': 'Wakamatsu Infection Leading Clinic'}]}, { 'given': 'Yasuhiko', 'family': 'Tsukada', 'sequence': 'additional', 'affiliation': [{'name': 'Fukushima Medical University'}]}, { 'given': 'Tomoyoshi', 'family': 'Lee', 'sequence': 'additional', 'affiliation': [{'name': 'Fukushima Medical University'}]}, { 'given': 'Ryuki', 'family': 'Yamada', 'sequence': 'additional', 'affiliation': [{'name': 'Fukushima Medical University'}]}, { 'given': 'Riko', 'family': 'Sato', 'sequence': 'additional', 'affiliation': [{'name': 'Fukushima Medical University'}]}, { 'given': 'Takumi', 'family': 'Onuma', 'sequence': 'additional', 'affiliation': [{'name': 'Fukushima Medical University'}]}, { 'given': 'Hikaru', 'family': 'Tomita', 'sequence': 'additional', 'affiliation': [{'name': 'Fukushima Medical University'}]}, { 'given': 'Mikako', 'family': 'Saito', 'sequence': 'additional', 'affiliation': [{'name': 'Fukushima Medical University'}]}, { 'given': 'Natsumi', 'family': 'Watanabe', 'sequence': 'additional', 'affiliation': [{'name': 'Fukushima Medical University'}]}, { 'given': 'Mami', 'family': 'Rikimaru', 'sequence': 'additional', 'affiliation': [{'name': 'Fukushima Medical University'}]}, { 'given': 'Takaya', 'family': 'Kawamata', 'sequence': 'additional', 'affiliation': [{'name': 'Fukushima Medical University'}]}, { 'given': 'Julia', 'family': 'Morimoto', 'sequence': 'additional', 'affiliation': [{'name': 'Fukushima Medical University'}]}, { 'given': 'Ryuichi', 'family': 'Togawa', 'sequence': 'additional', 'affiliation': [{'name': 'Fukushima Medical University'}]}, { 'given': 'Yuki', 'family': 'Sato', 'sequence': 'additional', 'affiliation': [{'name': 'Fukushima Medical University'}]}, { 'given': 'Junpei', 'family': 'Saito', 'sequence': 'additional', 'affiliation': [{'name': 'Fukushima Medical University'}]}, { 'given': 'Kenya', 'family': 'Kanazawa', 'sequence': 'additional', 'affiliation': [{'name': 'Fukushima Medical University'}]}, { 'given': 'Sugihiro', 'family': 'Hamaguchi', 'sequence': 'additional', 'affiliation': [{'name': 'Fukushima Medical University'}]}, { 'given': 'Ken', 'family': 'Iseki', 'sequence': 'additional', 'affiliation': [{'name': 'Fukushima Medical University'}]}], 'member': '8761', 'reference': [ { 'issue': '3', 'key': 'ref1', 'doi-asserted-by': 'publisher', 'first-page': '238', 'DOI': '10.1056/NEJMoa2035002', 'article-title': 'REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with ' 'Covid-19', 'volume': '384', 'author': 'Weinreich DM', 'year': '2021', 'unstructured': 'Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a ' 'Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J ' 'Med 2021; 384(3):238–51. https://doi.org/10.1056/NEJMoa2035002.', 'journal-title': 'N Engl J Med'}, { 'key': 'ref2', 'doi-asserted-by': 'publisher', 'first-page': '1236', 'DOI': '10.1001/jama.2022.2832', 'article-title': 'Effect of Sotrovimab on Hospitalization or Death Among High-risk ' 'Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial', 'volume': '327', 'author': 'Gupta A', 'year': '2022', 'unstructured': 'Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Effect of Sotrovimab on ' 'Hospitalization or Death Among High-risk Patients With Mild to Moderate ' 'COVID-19: A Randomized Clinical Trial. Jama 2022; 327:1236–46. ' 'https://doi.org/10.1001/jama.2022.2832.', 'journal-title': 'Jama'}, { 'key': 'ref3', 'doi-asserted-by': 'publisher', 'first-page': '509', 'DOI': '10.1056/NEJMoa2116044', 'article-title': 'Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients', 'volume': '386', 'author': 'Jayk Bernal A', 'year': '2022', 'unstructured': 'Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for ' 'Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med ' '2022; 386:509–20. https://doi.org/10.1056/NEJMoa2116044.', 'journal-title': 'N Engl J Med'}, { 'key': 'ref4', 'doi-asserted-by': 'publisher', 'first-page': '1397', 'DOI': '10.1056/NEJMoa2118542', 'article-title': 'Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19', 'volume': '386', 'author': 'Hammond J', 'year': '2022', 'unstructured': 'Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for ' 'High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med 2022; ' '386:1397–408. https://doi.org/10.1056/NEJMoa2118542.', 'journal-title': 'N Engl J Med'}, { 'key': 'ref5', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cell.2020.06.043', 'article-title': 'Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases ' 'Infectivity of the COVID-19 Virus', 'author': 'Korber B', 'year': '2020', 'unstructured': 'Korber B, Fischer WM, Gnanakaran S, et al. Tracking Changes in ' 'SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the ' 'COVID-19 Virus. Cell 2020; 182:812 – 27.e19. ' 'https://doi.org/10.1016/j.cell.2020.06.043.', 'journal-title': 'Cell'}, { 'key': 'ref6', 'doi-asserted-by': 'publisher', 'first-page': '21', 'DOI': '10.1038/d41586-021-03552-w', 'article-title': 'Heavily mutated Omicron variant puts scientists on alert', 'volume': '600', 'author': 'Callaway E', 'year': '2021', 'unstructured': 'Callaway E. Heavily mutated Omicron variant puts scientists on alert. ' 'Nature 2021; 600:21. https://doi.org/10.1038/d41586-021-03552-w.', 'journal-title': 'Nature'}, { 'key': 'ref7', 'doi-asserted-by': 'publisher', 'first-page': '29', 'DOI': '10.1093/jtm/taac037', 'article-title': 'The effective reproductive number of the Omicron variant of SARS-CoV-2 ' 'is several times relative to Delta', 'author': 'Liu Y', 'year': '2022', 'unstructured': 'Liu Y, Rocklöv J. The effective reproductive number of the Omicron ' 'variant of SARS-CoV-2 is several times relative to Delta. J Travel Med ' '2022; 29. https://doi.org/10.1093/jtm/taac037.', 'journal-title': 'J Travel Med'}, { 'key': 'ref8', 'doi-asserted-by': 'publisher', 'first-page': 'e0266270', 'DOI': '10.1371/journal.pone.0266270', 'article-title': 'Large-scale serosurveillance of COVID-19 in Japan: Acquisition of ' 'neutralizing antibodies for Delta but not for Omicron and requirement ' "of booster vaccination to overcome the Omicron's outbreak", 'volume': '17', 'author': 'Ren Z', 'year': '2022', 'unstructured': 'Ren Z, Nishimura M, Tjan LH, et al. Large-scale serosurveillance of ' 'COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but ' 'not for Omicron and requirement of booster vaccination to overcome the ' "Omicron's outbreak. PLoS One 2022; 17:e0266270. " 'https://doi.org/10.1371/journal.pone.0266270.', 'journal-title': 'PLoS One'}, { 'key': 'ref9', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cell.2021.12.032', 'article-title': 'The Omicron variant is highly resistant against antibody-mediated ' 'neutralization: Implications for control of the COVID-19 pandemic', 'author': 'Hoffmann M', 'year': '2022', 'unstructured': 'Hoffmann M, Krüger N, Schulz S, et al. The Omicron variant is highly ' 'resistant against antibody-mediated neutralization: Implications for ' 'control of the COVID-19 pandemic. Cell 2022; 185:447 – 56.e11. ' 'https://doi.org/10.1016/j.cell.2021.12.032.', 'journal-title': 'Cell'}, { 'key': 'ref10', 'doi-asserted-by': 'publisher', 'first-page': '490', 'DOI': '10.1038/s41591-021-01678-y', 'article-title': 'An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization ' 'by therapeutic monoclonal antibodies', 'volume': '28', 'author': 'VanBlargan LA', 'year': '2022', 'unstructured': 'VanBlargan LA, Errico JM, Halfmann PJ, et al. An infectious SARS-CoV-2 ' 'B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal ' 'antibodies. Nat Med 2022; 28:490–5. ' 'https://doi.org/10.1038/s41591-021-01678-y.', 'journal-title': 'Nat Med'}, { 'key': 'ref11', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S1473-3099(22)00507-2', 'article-title': 'Real-world effectiveness of early molnupiravir or ' 'nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without ' "supplemental oxygen requirement on admission during Hong Kong's omicron " 'BA.2 wave: a retrospective cohort study', 'author': 'Carlos KH', 'year': '2022', 'unstructured': 'Carlos K.H. Wong ICHA, Kristy T.K. Lau, Eric H. Y. Lau, Benjamin J. ' 'Cowling, Gabriel M. Leung. Real-world effectiveness of early ' 'molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with ' 'COVID-19 without supplemental oxygen requirement on admission during ' "Hong Kong's omicron BA.2 wave: a retrospective cohort study. Lancet " 'Infect Dis 2022. https://doi.org/10.1016/S1473-3099(22)00507-2.', 'journal-title': 'Lancet Infect Dis'}, { 'key': 'ref12', 'unstructured': 'The official website of Fukushima Prefecture. The variant of COVID-19 in ' 'Fukushima from January 2022 (in Japanese). ' 'https://www.pref.fukushima.lg.jp/site/covid19-portal/variant.html. ' 'Accessed 1 June 2022.'}, { 'key': 'ref13', 'unstructured': 'Japan Ministry of Health Labor and Welfare. Clinical Management of ' 'patients with COVID-19: A guide for front-line healthcare workers (in ' 'Japanese). Available at: ' 'https://www.niph.go.jp/h-crisis/wp-content/uploads/2020/07/20200706103735_content_000646531.pdf. ' 'Accessed 1 June 2022.'}, { 'key': 'ref14', 'doi-asserted-by': 'publisher', 'first-page': '3775', 'DOI': '10.3390/jcm10173775', 'article-title': 'Evaluation of Biomarkers of Severity in Patients with COVID-19 ' 'Infection', 'volume': '10', 'author': 'Yamamoto A', 'year': '2021', 'unstructured': 'Yamamoto A, Wada H, Ichikawa Y, et al. Evaluation of Biomarkers of ' 'Severity in Patients with COVID-19 Infection. J Clin Med 2021; 10:3775. ' 'https://doi.org/10.3390/jcm10173775.', 'journal-title': 'J Clin Med'}, { 'key': 'ref15', 'doi-asserted-by': 'publisher', 'author': 'Shibata Y', 'unstructured': 'Shibata Y, Minemura H, Suzuki Y, et al. Development and external ' 'validation of the DOAT and DOATS scores: simple decision support tools ' 'to identify disease progression among nonelderly patients with ' 'mild/moderate COVID-19. medRxiv [Preprint] December 14 2021. Available ' 'from:ã\u0ffd\u0ffdhttps://www.medrxiv.org/content/10.1101/2021.12.13.21267698v1.', 'DOI': '10.1101/2021.12.13.21267698v1'}, { 'key': 'ref16', 'doi-asserted-by': 'publisher', 'DOI': '10.2188/jea.JE20210145', 'article-title': 'Using Propensity Scores for Causal Inference: Pitfalls and Tips', 'author': 'Shiba K', 'year': '2021', 'unstructured': 'Shiba K, Kawahara T. Using Propensity Scores for Causal Inference: ' 'Pitfalls and Tips. J Epidemiol 2021; 31:457 – 63. ' 'https://doi.org/10.2188/jea.JE20210145.', 'journal-title': 'J Epidemiol'}, { 'key': 'ref17', 'doi-asserted-by': 'publisher', 'first-page': '150', 'DOI': '10.1002/pst.433', 'article-title': 'Optimal caliper widths for propensity-score matching when estimating ' 'differences in means and differences in proportions in observational ' 'studies', 'volume': '10', 'author': 'Austin PC', 'year': '2011', 'unstructured': 'Austin PC. Optimal caliper widths for propensity-score matching when ' 'estimating differences in means and differences in proportions in ' 'observational studies. Pharm Stat 2011; 10:150–61. ' 'https://doi.org/10.1002/pst.433.', 'journal-title': 'Pharm Stat'}, { 'key': 'ref18', 'doi-asserted-by': 'publisher', 'first-page': '319', 'DOI': '10.1038/s41422-022-00619-9', 'article-title': 'Reduced interferon antagonism but similar drug sensitivity in Omicron ' 'variant compared to Delta variant of SARS-CoV-2 isolates', 'volume': '32', 'author': 'Bojkova D', 'year': '2022', 'unstructured': 'Bojkova D, Widera M, Ciesek S, Wass MN, Michaelis M, Cinatl J Jr. ' 'Reduced interferon antagonism but similar drug sensitivity in Omicron ' 'variant compared to Delta variant of SARS-CoV-2 isolates. Cell Res 2022: ' '32:319–21. https://doi.org/10.1038/s41422-022-00619-9.', 'journal-title': 'Cell Res'}, { 'key': 'ref19', 'doi-asserted-by': 'publisher', 'first-page': '1475', 'DOI': '10.1056/NEJMc2201933', 'article-title': 'Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant ' 'BA.2', 'volume': '386', 'author': 'Takashita E', 'year': '2022', 'unstructured': 'Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of Antiviral ' 'Agents against the SARS-CoV-2 Omicron Subvariant BA.2. N Engl J Med ' '2022; 386:1475–7. https://doi.org/10.1056/NEJMc2201933.', 'journal-title': 'N Engl J Med'}, { 'key': 'ref20', 'doi-asserted-by': 'publisher', 'article-title': 'Different efficacies of neutralizing antibodies and antiviral drugs on ' 'SARS-CoV-2 Omicron subvariants, BA.1 and BA.2 Antiviral Res', 'author': 'Ohashi H', 'year': '2022', 'unstructured': 'Ohashi H, Hishiki T, Akazawa D, et al. Different efficacies of ' 'neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron ' 'subvariants, BA.1 and BA.2 Antiviral Res. 2022. ' 'https://doi.org/10.1016/j.antiviral.2022.105372.', 'DOI': '10.1016/j.antiviral.2022.105372'}, { 'key': 'ref21', 'doi-asserted-by': 'publisher', 'author': 'Rosenke K', 'unstructured': 'Rosenke K, Okumura A, Lewis MC, et al. Molnupiravir (MK-4482) is ' 'efficacious against Omicron and other SARS-CoV-2 variants in the Syrian ' 'hamster COVID-19 model. medRxiv [Preprint] February 24 2022 Available ' 'from: https://www.biorxiv.org/content/10.1101/2022.02.22.481491v1.', 'DOI': '10.1101/2022.02.22.481491v1'}, { 'key': 'ref22', 'doi-asserted-by': 'publisher', 'first-page': '345', 'DOI': '10.3390/antibiotics11030345', 'article-title': 'Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk ' 'Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study', 'volume': '11', 'author': 'Ong SWX', 'year': '2022', 'unstructured': 'Ong SWX, Ren D, Lee PH, et al. Real-World Use of Sotrovimab for ' 'Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An ' 'Observational Cross-Sectional Study. Antibiotics (Basel) 2022; 11:345. ' 'https://doi.org/10.3390/antibiotics11030345.', 'journal-title': 'Antibiotics (Basel)'}, { 'key': 'ref23', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/infdis/jiac206', 'article-title': 'Real World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab ' 'for Preventing Hospitalization and Mortality in COVID-19 Outpatients', 'author': 'Aggarwal NR', 'year': '2022', 'unstructured': 'Aggarwal NR, Beaty LE, Bennett TD, et al. Real World Evidence of the ' 'Neutralizing Monoclonal Antibody Sotrovimab for Preventing ' 'Hospitalization and Mortality in COVID-19 Outpatients. J Infect Dis ' '2022; 16;jiac206. https://doi.org/10.1093/infdis/jiac206.', 'journal-title': 'J Infect Dis'}, { 'key': 'ref24', 'doi-asserted-by': 'publisher', 'first-page': '174', 'DOI': '10.1016/j.jinf.2022.04.040', 'article-title': 'SARS-CoV-2 Omicron sublineage BA.2 replaces BA.1.1: Genomic ' 'surveillance in Japan from September 2021 to March 2022', 'volume': '85', 'author': 'Hirotsu Y', 'year': '2022', 'unstructured': 'Hirotsu Y, Maejima M, Shibusawa M, et al. SARS-CoV-2 Omicron sublineage ' 'BA.2 replaces BA.1.1: Genomic surveillance in Japan from September 2021 ' 'to March 2022. J Infect 2022; 85:174–211. ' 'https://doi.org/10.1016/j.jinf.2022.04.040.', 'journal-title': 'J Infect'}, { 'key': 'ref25', 'unstructured': 'The proportion of SARS-CoV-2 Omicron Subvariant BA.2 in Fukushima in ' 'April 2022 (in Japanese). ' 'https://www.minpo.jp/news/moredetail/2022041296103. Accessed 1 June ' '2022.'}, { 'key': 'ref26', 'doi-asserted-by': 'publisher', 'first-page': '2603', 'DOI': '10.1056/NEJMoa2034577', 'article-title': 'Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine', 'volume': '383', 'author': 'Polack FP', 'year': '2020', 'unstructured': 'Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the ' 'BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020; 383:2603–15. ' 'https://doi.org/10.1056/NEJMoa2034577.', 'journal-title': 'N Engl J Med'}], 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://www.researchsquare.com/article/rs-2118653/v1', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.researchsquare.com/article/rs-2118653/v1.html', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 10, 5]], 'date-time': '2022-10-05T18:37:26Z', 'timestamp': 1664995046000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.researchsquare.com/article/rs-2118653/v1'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 10, 5]]}, 'references-count': 26, 'URL': 'http://dx.doi.org/10.21203/rs.3.rs-2118653/v1', 'relation': {}, 'published': {'date-parts': [[2022, 10, 5]]}, 'subtype': 'preprint'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit